AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04257656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study NCT04257656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir placebo
Description: RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study NCT01494909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure plus
Description: Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
Study NCT02746276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftriaxone
Description: Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
Study NCT02371603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim 100 mg Tablet
Description: White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening
Study NCT00665548 — intervention group
Intervention type: RADIATION
Intervention: X-ray; magnetic resonance imaging
Description: Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences.
Study NCT01152372 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin, glucose and staple isotopes
Study NCT02571699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subgluteal Nerve Block
Description: ultrasound-guided subgluteal sciatic nerve block.
Study NCT02571699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subgluteal Nerve Block
Description: ultrasound-guided subgluteal sciatic nerve block.
Study NCT00055731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT00055731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Study NCT00055731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Study NCT00055731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Study NCT00055731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00195663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT00195663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00195663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab placebo
Study NCT00195663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate placebo
Study NCT00604695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Intracoronary injection of IV tenecteplase.
Study NCT00604695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Intracoronary injection of IV sterile saline
Study NCT03512392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative fluid and deresuscitation strategy
Description: Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
Study NCT00055731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate sodium
Study NCT00055731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Study NCT00055731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00055731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT03512392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care strategy
Description: Usual care at the discretion of the clinical team
Study NCT02661867 — intervention group
Intervention type: BEHAVIORAL
Intervention: delivery
Description: delivery either vaginal or by cesarean section
Study NCT02088021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico Transcatheter Aortic Valve
Description: Placement of the SJM Portico aortic valve with a ALC delivery system
Study NCT05311787 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: esophagectomy with simultaneous reconstruction
Description: Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
Study NCT03363620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic Brackets
Description: arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
Study NCT00055731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00055731 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT04051203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma Injection
Description: 60mL of blood will be drawn from the antecubital vein and processed via centrifugation. Samples will be centrifuged as per manufacturer instructions, yielding 5mL of PRP.
Study NCT04051203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrol and lidocaine
Description: Steroid injections will be prepared to include 20mg Depo-Medrol and 2mL 2% lidocaine.
Study NCT04051203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 2mL normal saline.
Study NCT03897283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle
Study NCT03897283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.
Study NCT04470063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055 tablets
Description: Multi-dose for DDO-3055 tablets
Study NCT04010721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Experiment 3
Description: Stimulation total duration from 10 to 600 ms
Study NCT03549247 — intervention group
Intervention type: BEHAVIORAL
Intervention: quality of life in healthy,gingivitis,periodontitis groups
Description: a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
Study NCT04470063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multi-dose for Placebo
Study NCT04293393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
Study NCT04293393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
Study NCT04293393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
Study NCT03363620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Brackets
Description: arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
Study NCT04293393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Study NCT04293393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Study NCT01162915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells.
Description: Intrathecal infusion of a single dose of ex vivo expanded MSC.
Study NCT03554447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet
Description: Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
Study NCT04293393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Analogue
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Study NCT03692832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LH
Description: Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally
Study NCT03692832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VH
Description: Vaginal hysterectomy following Heaney technique
Study NCT02130908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean fish
Description: Participants consumed 150g of lean fish, five times per week for 4 weeks
Study NCT02130908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty fish
Description: Participants consumed 150g of fatty fish, five times per week for 4 weeks
Study NCT02130908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean meat
Description: Participants consumed 150g of lean meat, five times per week for 4 weeks
Study NCT01521650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Patients will gurgle and swallow a mixture of probiotic bacteria
Study NCT04661644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)
Description: Dose: 1 x 10\^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)
Study NCT03554447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram 20 mg tablet + Placebo
Description: Selective serotonin reuptake inhibitor plus placebo
Study NCT02183233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica
Study NCT02183233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eschscholtzia Californica Placebo
Study NCT03747640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Transcranial Direct Current Stimulation (tDCS)
Description: tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
Study NCT03747640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based meditation
Description: The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
Study NCT03747640 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Self Transcranial Direct Current Stimulation (tDCS)
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
Study NCT03747640 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham meditation
Description: For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
Study NCT02735954 — intervention group
Intervention type: OTHER
Intervention: Marijuana
Description: This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
Study NCT04661644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)
Description: Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)
Study NCT02940496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir
Description: Given PO
Study NCT02940496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02940496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02940496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Given PO
Study NCT04374240 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AdNRGM
Description: AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]
Study NCT02080299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
Study NCT02080299 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
Study NCT00538070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sarcosine
Description: You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
Study NCT00538070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sarcosine
Description: You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
Study NCT00759421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: 12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Study NCT00759421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Study NCT00691184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
Study NCT00691184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride
Description: 10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
Study NCT00691184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
Study NCT00691184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
Study NCT02345213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: E2020 tablets will be orally administered once daily after breakfast
Study NCT02345213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be orally administered once daily after breakfast
Study NCT01622465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergometer cycling
Description: Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
Study NCT01622465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercises
Description: Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
Study NCT01290744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine 100mg daily for 12 months after completion of MDT.
Study NCT01290744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 12 months
Study NCT00898833 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT04994301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung T1 MRI
Description: Evaluation of lung T1 MRI to Assess Lung Disease
Study NCT01192308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40mg QD
Description: Tamoxifen 40mg QD during 4 weeks
Study NCT04325620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601
Description: HIP1601
Study NCT04325620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HGP1805
Description: Placebo of HIP1601
Study NCT01424033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 600mg by mouth, three times daily for 12 months
Study NCT04448210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DigiKnowIt News: Teen
Description: Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
Study NCT01991002 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 14/21 diet
Description: Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group.
Study NCT02485106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: 400mg three times per day for 28 days
Study NCT02485106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid or pentoxifylline
Description: Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
Study NCT00165425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echo/Stress Echo
Description: Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
Study NCT01314209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion